We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

42 hedge funds and large institutions have $25.7M invested in AYTU BioPharma in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 1 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,800% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 1

84% more capital invested

Capital invested by funds: $14M → $25.7M (+$11.8M)

1.2% more ownership

Funds ownership: 0.05% → 1.25% (+1.2%)

26% less funds holding

Funds holding: 57 → 42 (-15)

54% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 26

Holders
42
Holders Change
-15
Holders Change %
-26.32%
% of All Funds
0.74%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
12
Increased
19
Reduced
1
Closed
26
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$12.7M
2
AC
Armistice Capital
New York
+$12.1M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.08M
4
Citadel Advisors
Citadel Advisors
Florida
+$752K
5
PSC
Piper Sandler & Co
Minnesota
+$452K

Top Sellers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
-$118K
2
AllianceBernstein
AllianceBernstein
Tennessee
-$109K
3
Jane Street
Jane Street
New York
-$68K
4
VCA
Verdence Capital Advisors
Maryland
-$67K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$40K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$8.37M +$12.7M +69,939 New
AC
2
Armistice Capital
New York
$7.97M +$12.1M +66,667 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$4.16M +$1.08M +5,928 +21%
BlackRock
4
BlackRock
New York
$1.84M +$84.3K +463 +3%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$618K +$343K +1,885 +57%
Citadel Advisors
6
Citadel Advisors
Florida
$500K +$752K +4,128 +7,371%
PSC
7
Piper Sandler & Co
Minnesota
$297K +$452K +2,480 New
State Street
8
State Street
Massachusetts
$295K +$185K +1,014 +70%
Northern Trust
9
Northern Trust
Illinois
$293K +$20.9K +115 +5%
Principal Financial Group
10
Principal Financial Group
Iowa
$235K +$358K +1,966 New
Squarepoint
11
Squarepoint
New York
$208K +$317K +1,743 New
WG
12
Winton Group
United Kingdom
$171K +$261K +1,433 New
Commonwealth Equity Services
13
Commonwealth Equity Services
Massachusetts
$147K +$90.5K +497 +67%
Wells Fargo
14
Wells Fargo
California
$108K +$36.2K +199 +28%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$89K +$63K +346 +87%
Morgan Stanley
16
Morgan Stanley
New York
$87K +$126K +693 +1,612%
SC
17
Searle & Co
Connecticut
$84K +$59.2K +325 +87%
Charles Schwab
18
Charles Schwab
California
$66K – – –
JP Morgan Chase
19
JP Morgan Chase
New York
$45K +$36.8K +202 +115%
UBS Group
20
UBS Group
Switzerland
$42K +$64.3K +353 New
New York State Common Retirement Fund
21
New York State Common Retirement Fund
New York
$40K – – –
California State Teachers Retirement System (CalSTRS)
22
California State Teachers Retirement System (CalSTRS)
California
$21K – – –
TRCT
23
Tower Research Capital (TRC)
New York
$15K +$3.46K +19 +17%
Deutsche Bank
24
Deutsche Bank
Germany
$10K +$4.19K +23 +40%
CA
25
Clearstead Advisors
Ohio
$8K – – –
1
2 3

AYTU Hedge Fund Activity: Q4 2020 in Review

42 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2020, worth a combined $25.7M — up 84% from $14M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of AYTU and 12 opened new positions — a net loss of 14 holders — while 1 trimmed existing stakes and 19 added.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $12.7M. The largest seller was Nuveen, exiting entirely with an estimated $118K sold.

  • 42 institutional investors held AYTU BioPharma (AYTU) as of Q4 2020, down from 57 in Q3 2020.
  • Funds reported $25.7M of AYTU BioPharma stock for Q4 2020, up 84% quarter-over-quarter.
  • 12 funds opened new AYTU BioPharma positions in Q4 2020 and 26 closed out, a net change of -14 holders.
  • The largest AYTU BioPharma buyer in Q4 2020 was Stonepine Capital Management, an estimated $12.7M added.
  • The largest AYTU BioPharma seller in Q4 2020 was Nuveen, an estimated $118K sold.

Based on aggregated 13F filings for Q4 2020.